Armatus Announces Groundbreaking Data Supporting TVR110, a Vectorized MicroRNA Therapy for the Treatment of Charcot-Marie-Tooth Disease Type 1A

AI Briefing

• – Armatus announces TVR110 vectorized microRNA therapy for Charcot-Marie-Tooth Disease Type 1A, based on data published in Molecular Therapy Nucleic Acids.
• – TVR110 shows promise as a first-in-class treatment for CMT1A, a subtype of Charcot-Marie-Tooth Disease.
• – Armatus to proceed with further clinical trials for TVR110.